In-vitro and ex-vivo neutralizing effect of protamine sulphate on the anticoagulant activity of a new low molecular mass heparin.
Falkon
L
L
Unitat d'Hemostàsia i Trombosi, Institut de Recerca, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Garí
M
M
Gich
I
I
Fontcuberta
J
J
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D000990:Antithrombin III / Q000187:drug effects / Q000378:metabolism; D001777:Blood Coagulation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D006494:Heparin Antagonists / Q000494:pharmacology*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D011479:Protamines / Q000494:pharmacology*; D011517:Prothrombin Time; D012016:Reference Values; D013918:Thrombin Time
D000925:Anticoagulants; D006494:Heparin Antagonists; D006495:Heparin, Low-Molecular-Weight; D011479:Protamines; D000990:Antithrombin III